Comparison of the direct antiglobulin test and the eluate technique for diagnosing haemolytic disease of the newborn  by van Rossum, Huub H. et al.
Contents lists available at ScienceDirect
Practical Laboratory Medicine
Practical Laboratory Medicine 3 (2015) 17–22http://d
2352-55
(http://c
n Corr
E-mjournal homepage: www.elsevier.com/locate/plabmComparison of the direct antiglobulin test and the eluate
technique for diagnosing haemolytic disease of the newbornHuub H. van Rossum a, Nelly de Kraa a, Melanie Thomas b, Cas A.G. Holleboom c,
Ad Castel a, André P. van Rossum a,n
a Department of Clinical Chemistry and Haematology, Bronovo Hospital, The Hague, The Netherlands
b Department of Pediatrics, Bronovo Hospital, The Hague, The Netherlands
c Department of Obstetrics and Gynaecology, Bronovo Hospital, The Hague, The Netherlandsa r t i c l e i n f o
Article history:
Received 29 July 2015
Received in revised form
7 October 2015
Accepted 10 October 2015
Available online 22 October 2015
Keywords:
DAT
Haemolytic disease of the newborn
Eluate
Test performance
Sensitivity
Specificity
NPV
PPVx.doi.org/10.1016/j.plabm.2015.10.001
17/& 2015 The Authors. Published by Elsevi
reativecommons.org/licenses/by-nc-nd/4.0/)
espondence to: Bronovolaan 5, 2597 AX The
ail address: apvrossum@bronovo.nl (A.P. vana b s t r a c tObjective: The direct antiglobulin test (DAT) is an important tool for identification of
haemolytic disease of the newborn (HDN) caused by erythrocyte immunization. Although
this test has been used for decades, accurate insights into its diagnostic properties and
optimal use in the diagnosis of HDN are limited. We aimed to gain more insight into the
diagnostic properties of the DAT for HDN by comparing it with erythrocyte eluate
screening.
Design and methods: DAT and erythrocyte eluate screening was performed in umbilical
cord blood of neonates obtained from 317 consecutive deliveries. Clinical jaundice was
scored 4–6 days after delivery for the determination of HDN.
Results: In 21 neonates a positive DAT and in 61 neonates a positive eluate screening was
found, while only 4 cases of HDN were observed. For the overall population the positive
predictive value (PPV) and specificity of the DAT for HDN were 10% and 93% respectively
and in the population of neonates with abnormal post-partum jaundice population the
PPV and specificity were both 100%. The DAT missed two cases of HDN. These missed
cases were, however, positive in the erythrocyte eluate screening.
Conclusion: The detection of clinically irrelevant ABO immunization limits the specificity
of the DAT and eluate for HDN in ABO-incompatible pregnancies. For optimal use, the DAT
should be requested only in cases of jaundice and be interpreted in the context of ABO-
incompatibility. Finally, a negative DAT does not rule out HDN. When clinical suspicion is
high, an eluate should be added following a negative DAT.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Classically, the direct antiglobulin test (DAT), or direct Coombs test, plays a central role in diagnosing haemolytic disease
of the newborn (HDN) caused by foetal erythrocyte immunisation [1]. This condition is characterized by the presence of
maternal blood group antibodies in the circulation of the foetus/neonate. These maternal antibodies are able to cross the
placental blood barrier and are either directed against the A or B antigens of the regular ABO blood group, or antigens of one
of the other blood group systems. HDN may lead to severe haemolysis, jaundice and kernicterus [1,2]. Adequate diagnosticer B.V. This is an open access article under the CC BY-NC-ND license
.
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and hepatic or infectious causes of jaundice. HDN by Rh D immunization is probably the best known variant due to its high
incidence and severe clinical symptoms. Hence, several countries established programmes for the prevention and mon-
itoring of Rh D immunization in pregnant Rh D negative women [1,2].
For diagnosis of HDN by pregnancy immunization, detection of neonatal erythrocytes sensitized with immunoglobins is
a keystone diagnostic requirement. The DAT is a suitable test for this purpose. In the DAT assay, (neonatal) erythrocytes are
incubated with polyclonal anti-human (IgG) antibodies. Erythrocytes sensitized with anti-erythrocyte immunoglobulin
(IgG) agglutinate due to cross-linking of these erythrocytes. However the DAT does not determine the specificity of the
bound antibody. For antibody identification, elution of erythrocyte bound antibody, followed by binding analysis of the
antibody present in the eluate against test erythrocytes of well known erythrocyte blood group phenotype, is performed.
Elution of the antibodies from sensitized erythrocytes can be performed using different approaches including ether or acid,
or by freezing. Apart from identification of antibody specificity, elution techniques can also be used for screening of sen-
sitized erythrocytes [3]. In general, elution techniques are more sensitive in detecting anti-erythrocyte antibodies compared
to the DAT [4]. However, these techniques are often only available in specialized laboratories, require larger blood volumes
and are laborious [3]. Especially for neonatal erythrocytes, a limited sensitivity of the DAT for anti-A (IgG) and anti-B (IgG)
compared to other techniques has been reported [5].
In a recent case in our hospital, a negative DAT was found in a neonate with no other obvious cause of neonatal jaundice
and a known neonatal/maternal blood group incompatibility (Apos/Oneg). Due to the high clinical suspicion of HDN by
pregnancy immunization an eluate was prepared from neonatal erythrocytes and screened for the presence of anti-A and
irregular erythrocyte blood group antibodies. This resulted in the identification of IgG anti-A antibodies. The discrepancy
between the DAT and elution technique in this case triggered us to investigate the use of these techniques for the analysis of
HDN. Despite the commonly accepted use of the DAT in the diagnosis of HDN, the sensitivity, specificity and predictive
values of this test for HDN by immunization are poorly documented. In this study we investigated the predictive value of
both the DAT and elution techniques in suspected and unsuspected HDN.2. Patients and methods
2.1. Patients and study set-up
Neonates from 317 consecutive deliveries in our hospital were included in this study. Informed consent was obtained
from each participant.
ABOD blood type of the mother was determined previously for the Dutch prophylactic anti-D programme. In this pro-
gramme, all Rh D negative pregnant women received anti-Rh D treatment with polyclonal anti-Rh D (IgG, CDL Behring) in
week 30 of pregnancy.
Post-partum, 7 mL of venous lithium–heparin anticoagulated blood from the mother and 7 mL lithium–heparin antic-
oagulated umbilical cord blood were collected. Umbilical cord blood was analysed for ABOD and DAT by column (Low Ionic
Strength Solution (LISS), Bio-Rad Laboratories, Hercules, CA, USA), and Polyethylene-glycol (PEG) methods. Erythrocyte
eluates were prepared by freeze and ether elution methods. Eluates were screened for irregular blood group antibodies
using a 3 cell panel and, in cases of maternal/neonatal ABO-incompatibility, also for the presence of IgG anti-A or anti-B
antibodies. In the event of positive screening of the eluate, venous blood of the mother was used for irregular antibody
identification. In addition, titres of anti-blood group antibodies were determined in umbilical cord and maternal plasma.
In order to avoid invasive blood collection for measurement of bilirubin, a non-invasive jaundice score was used. The
jaundice was scored 4–6 days postpartum, using the following self-defined criteria: jaundice of the face, chest, sclera and
mouth/tongue was scored as absent (0 points), little (1 point), clearly present (2 points). The minimal jaundice score was
0 and the maximal score was 8. A jaundice score of Z4 was considered as abnormal post partum jaundice. HDN by foetal
erythrocyte immunization was defined as: a jaundice score of Z4 as well as serological evidence for erythrocyte im-
munization by DAT or elution techniques, in the absence of other causes of abnormal post partum jaundice.
2.2. ABOD blood group determination
The ABO-Rh D blood groups of the neonate and the mother were determined by a direct antiglobulin technique (salt
phase-enhanced) using agglutination of monoclonal antibodies against A1, B, D and enhanced D for forward ABO grouping
and A1 and B test erythrocytes for reverse ABO grouping. Antibodies and test erythrocytes were purchased from Sanquin
(Amsterdam, The Netherlands).
2.3. DAT
The DAT was performed manually in a manual agglutination mode and in the LISS/column mode. For the manual ag-
glutination mode, erythrocytes were washed 3 times with cold 0.9% NaCl. A 3% erythrocyte solution was obtained by adding
33 drops (1.2 mL) of 0.9% NaCl to 1 drop of washed erythrocytes. Next, 2 drops of polyspecific anti-human IgG (Sanquin,
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cells were gently resuspended and agglutination was scored macroscopically and categorized as negative (), weak (þ/)
or positive (1þ , 2þ , 3þ , 4þ).
The LISS/column mode was performed with LISS/Coombs cards (Bio-Rad Laboratories, Hercules, CA, USA) containing both
anti-IgG and anti-C3d antibodies, according to the manufacturer's instructions. Agglutination was scored on a similar po-
sitivity scale to the manual agglutination method.
2.4. Antibody elution methods
Antibody elution from umbilical cord erythrocytes was performed by both freeze and ether elution methods. Ery-
throcytes were washed 6 times with cold 0.9% NaCl. The supernatant of the last washing was used as negative control.
For the freeze elution method, 5 drops of packed washed erythrocytes were mixed with 1 drop of 22% bovine serum
albumin (BSA) (Sanquin, Amsterdam, The Netherlands) and frozen for at least 10 min at 40 °C. After thawing at 37 °C and
centrifugation (800g, 10 min) the supernatant was collected and analyzed for antibodies.
Ether eluates were prepared by addition of 1 part 0.9% NaCl and 3 parts diethyl ether to 2 parts of packed and washed
erythrocytes. This was mixed for 1 min and incubated for 30 min at 37 °C. After centrifugation (800g, 10 min) the lower layer
was collected. The last step was repeated and the remaining fraction (eluate) was analyzed for antibodies.
2.5. Identification of anti-ABO (IgG) and irregular blood group antibodies
In cases of ABO-incompatible pregnancies, eluates were analysed for IgG anti-A and anti-B antibodies by use of A1 and B
cells (Sanquin) respectively. When positive, 1:1 serial dilutions of neonatal plasma were obtained for IgG anti-A and/or anti-
B titre determination. In addition, maternal plasma was analysed for relevant IgG anti-ABO antibodies and antibody titres.
Maternal plasma was diluted 1:1 with 0.01 M dithiothreitol (DTT) in 0.9% NaCl and incubated for 15 min at 37 °C. Mono-
clonal Rh D IgM antibodies treated with and without 0.01 M DTT tested on Rh D positive erythrocytes were used as controls.
Antibody titres from maternal blood were determined by testing different dilutions (1:2–1:15,000) in a salt-phase indirect
antiglobulin technique using agglutination of A1 or B positive erythrocytes as detection technique. In this technique anti-
bodies against A1 or B were agglutinated by using polyspecific anti-human globulin directed against IgG and C3d according
to the manufacturer's recommendations (Sanquin; Amsterdam, The Netherlands).
For detection of irregular antibodies, eluates were screened using a panel of 3 erythrocyte screening cells (Sanquin) in a
PEG-phase indirect antiglobulin test. When positive, antibody identification was performed in maternal heparin plasma
using an 11-cell antibody identification panel (Sanquin).3. Results
3.1. Clinical findings
Jaundice was scored in 282 of 317 neonates. In 33 cases the jaundice-score was Z4. In 9 of these, the abnormal post-
partum jaundice score coincided with a positive identification of sensitized neonatal erythrocytes. In 4 of these only anti-D
was found on neonatal erythrocytes which could be ascribed to prophylactic administered anti-Rh D during pregnancy. For
this reason these were not classified as HDN by pregnancy immunisation. In 1 of the 9 suspected cases the jaundice was
most likely caused by infection, therefore this neonate was also excluded. All together, based on our criteria, 4 cases of HDN
were found in this cohort (Table 1).
3.2. Serological findings
In the group of ABO compatible pregnancies (238), one case of positive DAT and positive eluate was found. The antibody
specificity was anti-E and this neonate had a jaundice score of 0. An overview of the results found in the ABOD-incompatible
pregnancies is presented in Table 2.Table 1
Characteristics of four neonates diagnosed with HDN.
Delivery Jaundice score DAT Eluate Ab PT Bilirubin (μmol/L) Ab titre mother Ab titre neonate
1 Vacuum extraction 7  1þ anti-A  159 1:128 –
2 Forceps extraction 5 1þ 2þ anti-A  164 1:4000 1:2
3 Spontaneous partus 4  1þ anti-A  ND 1:128 1:1
4 Spontaneous partus 8 2þ 2þ anti-A þ 297 1:1024 1:32
Ab: antibody specificity; PT: phototherapy; ND: not determined.
Table 2
Serological findings for ABOD incompatible pregnancies.
ABO-incompatibility ABO-compatible Rhesus-D
Mother 0 0 A A B B (other than anti-D) –
Neonate A B B AB A AB þ
Total number 46 14 5 6 3 5 238 31
Pos DAT 18 1 0 0 0 0 1a 2b
Pos eluate 37 4 0 0 1 1 1a 18b
Neg DAT 28 13 5 6 3 5 237 29
Neg eluate 9 10 5 6 2 4 237 13
jaundice score Z 4 4 2 2 2 0 1 22 5
HDN 3 0 0 0 0 1 0 0
For each type of ABO-incompatible and Rhesus D incompatible pregnancy, the number of positive DAT, eluate, jaundice score and HDN are presented.
a Caused by anti-E.
b 1 Anti-A antibodies present in DAT and 2 in eluate. For all negative eluates, DAT was also negative.
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positive eluate was observed. Especially in the group of blood group 0 mothers with a neonate blood group A (AO-antag-
onism), a high incidence of positive DAT and eluate was found; 39% (18/46) and 80% (37/46) respectively.
All observed anti-Rh D antibodies could be ascribed to prophylactic anti-Rh D. These antibodies were either not de-
monstrable or demonstrable in low titres in maternal serum.3.3. Predictive values for HDN
In order to investigate the diagnostic properties of the DAT and eluate, the predictive values, sensitivity and specificity
were calculated for the total population, for neonates with a jaundice score of Z4 and for ABO-incompatible pregnancies
(Table 3). All but two positive DAT were caused by anti-A IgG or anti-B IgG antibodies. The majority of the positive eluate
findings were caused by anti-A IgG or anti-B IgG antibodies and prophylactically administered anti-D. As a consequence, the
predictive values and sensitivity/specificity presented, especially for the DAT are almost exclusively related to ABO-blood
group incompatibility.
The positive predictive value (PPV) calculated from the total population wasr10% for DAT and eluate. In addition, a
limited specificity of 93% and 80% for DAT and eluate respectively was found due to the frequent presence of anti-A (andTable 3
Diagnostic accuracy of DAT and eluate.
Total population Jaundice scoreZ4 ABO incompatible
HDN and DAT (n) 259 29 53
HDNþ and DATþ (n) 2 2 2
HDN and DATþ (n) 19 0 17
HDNþ and DAT (n) 2 2 2
Sensitivity DAT (%) 50 50 50
Specificity DAT (%) 93 100 76
PPV DAT (%) 10 100 11
NPV DAT (%) 99 94 96
HDN and Eluate (n) 222 28 31
HDNþ and Eluateþ (n) 4 4 4
HDN and Eluateþ (n) 56 1 39
HDNþ and Eluate (n) 0 0 0
Sensitivity eluate (%) 100 100 100
Specificity eluate (%) 80 97 44
PPV eluate (%) 7 80 9
NPV eluate (%) 100 100 100
Missing valuesa 35 NA 5
Total (n) 282 33 74
Table includes numbers (n) of true and false positive and negative findings, sensitivity, specificity and predictive values for HDN. Parameters were cal-
culated for the total population, neonates with a jaundice score of Z4 and ABO-incompatible pregnancies.
NA: not applicable.
a Missing values are caused by the absence of a jaundice score.
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set-up for HDN in the overall population. To illustrate the relevance of ABO-incompatibility, the predictive values and
sensitivity and specificity are also calculated for this population. In general clinical practice a DAT is most often performed in
cases of a clinical suspicion of HDN. Therefore, the diagnostic properties of the DAT and eluate, were also calculated for the
population with a jaundice score of Z4. These results are all presented in Table 3.4. Discussion
In this study, anti-erythrocyte antibodies detected by eluate and/or DAT were mainly observed in ABO-incompatible
pregnancies. All observed anti-D antibodies could be explained by prophylactic administered anti-Rh D. Since only one other
antibody (anti-E) was detected in our population, ABO-incompatible pregnancy was by far the major cause of positive DAT
and eluate screening. Despite the fact that this observation is specific for this population, due to the Dutch programme for
prevention of anti-D immunisation and the cEK compatible transfusion policy in our hospital for women under 45 years, it
does illustrate the relevance of ABO-incompatible pregnancies for finding a positive DAT and/or eluate screening.
In the group of A/O-incompatible pregnancies 37 (80%)occurrences of an anti-A antibody were found on the neonatal
erythrocyte using eluate screening and 18 occurrences (39%) using DAT, while only 4 cases (9%) of this group presented with
abnormal post partum jaundice. This discrepancy illustrates the high sensitivity of both techniques for detecting neonatal
erythrocytes sensitized with anti-A and anti-B. Especially for A/O-incompatible pregnancies it appears that some degree of
sensitization of neonatal erythrocytes with maternal IgG anti-A occurs regularly. The question arises as to the clinical re-
levance of this phenomenon. Lower haematocrit values have been reported for the group of ABO-incompatible as well as
DAT-positive neonates [6,7]. This suggests that, despite the lack of obvious clinical jaundice, some degree of haemolysis
could very well be present. Unfortunately, we were unable to investigate the relevance of this observation in our study, since
no material was available for biochemical analysis of haemolysis and haemoglobin. The observed phenomenon of “sub-
clinical” erythrocyte sensitization results in a low positive predictive value and specificity for both DAT as well as eluate
screening [8]. Screening for HDN by DAT results in many false positive results. One should be aware that in cases of ABO-
incompatible pregnancies large percentages of positive neonatal DAT results are observed in the absence of clinical jaundice.
The use of DAT for screening purposes therefore remains controversial and will result in a large amount of false positive
results [8–11]. For diagnosing HDN in ABO-incompatible pregnancies, additional information such as neonatal haemolysis
and high titres of antibody present in the mother could be helpful to improve the diagnostic accuracy.
The calculated sensitivity of DAT and eluate screening for HDN in this population lacks accuracy due to the limited
statistical power caused by the low incidence of HDN [12,13]. In 317 consecutive pregnancies only 4 (1.3%) cases of HDN
were observed according to our criteria. However, this study gives accurate insights in the specificity of the DAT and eluate
screening for HDN. The requirement of serological evidence of erythrocyte sensitization for determination of HDN by
pregnancy immunisation together with the low incidence in this group (approximately 10%) is responsible for the high NPV
of the DAT and a NPV for eluate screening of 100%. The latter is caused by the higher analytical sensitivity of eluate screening
compared to the DAT for anti-A and anti-B. For detection of other blood group antagonism caused by irregular blood group
systems, the DAT probably has a better analytical sensitivity which is more comparable to the analytical sensitivity of eluate
screening. This can be explained by the low neonatal erythrocyte expression of the A- and B-antigens [15].
The PPV for HDN in the jaundice group is much higher compared to the overall population due to the increased in-
cidence, but is still imprecise due to the small number of positive HDN cases.
Other groups have reported a higher sensitivity in a comparable population (86%) and postulate that in cases of DAT
negative HDN, other causes of hyperbilirubinemia should be sought [8,14]. In our study the DAT missed 2 cases of HDN. This
might also be explained by the higher analytical sensitivity of the eluate technique for detecting erythrocyte-bound anti-
bodies together with coincidence of other non-specified causes of jaundice [3,5]. The more sensitive eluate screening
technique was not used in these previous studies.5. Conclusion
The DAT has limited sensitivity for HDN and is therefore an invaluable screening tool for HDN. In addition, a positive DAT
should be interpreted in the context of ABO-incompatibility because of its limited specificity in these pregnancies. In cases
of a strong clinical suspicion for HDN together with a negative DAT, a second, more sensitive test such as eluate screening
should be performed in order to rule out or confirm the diagnosis.Funding source
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